151 related articles for article (PubMed ID: 37414805)
1. Unbiased proteomics and multivariable regularized regression techniques identify SMOC1, NOG, APCS, and NTN1 in an Alzheimer's disease brain proteomic signature.
Roberts JA; Varma VR; Candia J; Tanaka T; Ferrucci L; Bennett DA; Thambisetty M
NPJ Aging; 2023 Jul; 9(1):18. PubMed ID: 37414805
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study.
Mahajan UV; Varma VR; Griswold ME; Blackshear CT; An Y; Oommen AM; Varma S; Troncoso JC; Pletnikova O; O'Brien R; Hohman TJ; Legido-Quigley C; Thambisetty M
PLoS Med; 2020 Jan; 17(1):e1003012. PubMed ID: 31978055
[TBL] [Abstract][Full Text] [Related]
3. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M
PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.
Davatzikos C; Xu F; An Y; Fan Y; Resnick SM
Brain; 2009 Aug; 132(Pt 8):2026-35. PubMed ID: 19416949
[TBL] [Abstract][Full Text] [Related]
5. A multi-omics study to monitor senescence-associated secretory phenotypes of Alzheimer's disease.
Yang J; Zhou Y; Wang T; Li N; Chao Y; Gao S; Zhang Q; Wu S; Zhao L; Dong X
Ann Clin Transl Neurol; 2024 May; 11(5):1310-1324. PubMed ID: 38605603
[TBL] [Abstract][Full Text] [Related]
6. eNetXplorer: an R package for the quantitative exploration of elastic net families for generalized linear models.
Candia J; Tsang JS
BMC Bioinformatics; 2019 Apr; 20(1):189. PubMed ID: 30991955
[TBL] [Abstract][Full Text] [Related]
7. Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study.
Varma VR; Wang Y; An Y; Varma S; Bilgel M; Doshi J; Legido-Quigley C; Delgado JC; Oommen AM; Roberts JA; Wong DF; Davatzikos C; Resnick SM; Troncoso JC; Pletnikova O; O'Brien R; Hak E; Baak BN; Pfeiffer R; Baloni P; Mohmoudiandehkordi S; Nho K; Kaddurah-Daouk R; Bennett DA; Gadalla SM; Thambisetty M
PLoS Med; 2021 May; 18(5):e1003615. PubMed ID: 34043628
[TBL] [Abstract][Full Text] [Related]
8. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?
Whitwell JL; Tosakulwong N; Weigand SD; Senjem ML; Lowe VJ; Gunter JL; Boeve BF; Knopman DS; Dickerson BC; Petersen RC; Jack CR
Neuroimage Clin; 2013; 2():249-57. PubMed ID: 24179779
[TBL] [Abstract][Full Text] [Related]
9. Exploring brain glucose metabolic patterns in cognitively normal adults at risk of Alzheimer's disease: A cross-validation study with Chinese and ADNI cohorts.
Li TR; Dong QY; Jiang XY; Kang GX; Li X; Xie YY; Jiang JH; Han Y;
Neuroimage Clin; 2022; 33():102900. PubMed ID: 34864286
[TBL] [Abstract][Full Text] [Related]
10. The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome.
Drummond E; Kavanagh T; Pires G; Marta-Ariza M; Kanshin E; Nayak S; Faustin A; Berdah V; Ueberheide B; Wisniewski T
Acta Neuropathol Commun; 2022 Apr; 10(1):53. PubMed ID: 35418158
[TBL] [Abstract][Full Text] [Related]
11. Multi-Omics, an Integrated Approach to Identify Novel Blood Biomarkers of Alzheimer's Disease.
François M; Karpe AV; Liu JW; Beale DJ; Hor M; Hecker J; Faunt J; Maddison J; Johns S; Doecke JD; Rose S; Leifert WR
Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295851
[TBL] [Abstract][Full Text] [Related]
12. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression.
Bai B; Wang X; Li Y; Chen PC; Yu K; Dey KK; Yarbro JM; Han X; Lutz BM; Rao S; Jiao Y; Sifford JM; Han J; Wang M; Tan H; Shaw TI; Cho JH; Zhou S; Wang H; Niu M; Mancieri A; Messler KA; Sun X; Wu Z; Pagala V; High AA; Bi W; Zhang H; Chi H; Haroutunian V; Zhang B; Beach TG; Yu G; Peng J
Neuron; 2020 Mar; 105(6):975-991.e7. PubMed ID: 31926610
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study.
Xicota L; Ichou F; Lejeune FX; Colsch B; Tenenhaus A; Leroy I; Fontaine G; Lhomme M; Bertin H; Habert MO; Epelbaum S; Dubois B; Mochel F; Potier MC;
EBioMedicine; 2019 Sep; 47():518-528. PubMed ID: 31492558
[TBL] [Abstract][Full Text] [Related]
14. Possibility of Enlargement in Left Medial Temporal Areas Against Cerebral Amyloid Deposition Observed During Preclinical Stage.
Imabayashi E; Ishii K; Toyohara J; Wagatsuma K; Sakata M; Tago T; Ishibashi K; Kojima N; Kohda N; Tokumaru AM; Kim H
Front Aging Neurosci; 2022; 14():847094. PubMed ID: 35517046
[TBL] [Abstract][Full Text] [Related]
15. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort.
Hirtz C; Busto GU; Bennys K; Kindermans J; Navucet S; Tiers L; Lista S; Vialaret J; Gutierrez LA; Dauvilliers Y; Berr C; Lehmann S; Gabelle A
Alzheimers Res Ther; 2023 Feb; 15(1):34. PubMed ID: 36800984
[TBL] [Abstract][Full Text] [Related]
17. Vascular risk is not associated with PET measures of Alzheimer's disease neuropathology among cognitively normal older adults.
Bilgel M; Bannerjee A; Shafer A; An Y; Resnick SM
Neuroimage Rep; 2021 Dec; 1(4):. PubMed ID: 34927122
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Peripheral Transport Proteins and Plasma Amyloid-β in Patients with Alzheimer's Disease Were Different from Cognitively Normal Controls: A Propensity Score Matching Analysis.
Gao L; Wang J; Jiang Y; Wei S; Shang S; Chen C; Dang L; Huo K; Deng M; Wang J; Qu Q
J Alzheimers Dis; 2020; 78(2):699-709. PubMed ID: 33016902
[TBL] [Abstract][Full Text] [Related]
19. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease.
Mendonça CF; Kuras M; Nogueira FCS; Plá I; Hortobágyi T; Csiba L; Palkovits M; Renner É; Döme P; Marko-Varga G; Domont GB; Rezeli M
Neurobiol Dis; 2019 Oct; 130():104509. PubMed ID: 31207390
[TBL] [Abstract][Full Text] [Related]
20. Amyloid beta-correlated plasma metabolite dysregulation in Alzheimer's disease: an untargeted metabolism exploration using high-resolution mass spectrometry toward future clinical diagnosis.
Yang J; Wu S; Yang J; Zhang Q; Dong X
Front Aging Neurosci; 2023; 15():1189659. PubMed ID: 37455936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
